Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer

Video

Mike Cusnir, MD, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Mike Cusnir, MD, co-director of Gastrointestinal Malignancies at Mount Sinai Medical Center, discusses the utility of regorafenib (Stivarga) in gastric cancer.

Regorafenib is still in the early stages of development in gastric cancer, says Cusnir. Although regorafenib has shown activity in this space, it is also one of the more toxic agents. As such, it is unknown what its optimal role will be in the treatment paradigm.

In colorectal cancer, the phase II ReDOS trial demonstrated that a dose-escalation strategy could be used with regorafenib to reduce associated adverse events and maintain efficacy; however, it is unknown whether the same holds true in gastric cancer. In the absence of those data, the field is looking toward larger confirmatory trials to establish whether regorafenib has a role in subsequent lines of gastric cancer treatment, concludes Cusnir.  

Related Videos
In this second episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, explain the challenges faced with preventing or detecting these cancers early and the understanding that is needed to develop effective early detection methods and move the needle forward.
In this first episode of OncChats: Leveraging Immunotherapy in GI Malignancies, Toufic Kachaamy, MD, of City of Hope, Sunil Sharma, MD, of City of Hope, and Madappa Kundranda, MD, PhD, of Banner MD Anderson Cancer Center, discuss the potential for early detection multiomic assays and the work that still needs to be done to encourage their widespread use.
Emmanuel Antonarakis, MD, associate director, Translational Research, Masonic Cancer Center, University of Minnesota, Clark Endowed Professor of Medicine, University of Minnesota Medical School
Gautam Jha, MD, medical director, M Health Fairview Masonic Cancer Clinic and the Advanced Treatment Center at the M Health Fairview Clinics and Surgery Center—Minneapolis, chair, cancer committee, M Health Fairview Ridges Hospital
Ricardo D. Parrondo, MD, hematologist/oncologist, Mayo Clinic
Ilyas Sahin, MD
Raj Singh, MD
Jaime R. Merchán, MD, professor, co-leader, Translational and Clinical Oncology Research Program, director, Phase 1 Clinical Trials Program, Department of Medicine, Division of Medical Oncology, the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center
Saad J. Kenderian, MB, CHB
Tycel Phillips, MD